Home self-administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days

被引:39
|
作者
Kallner, H. Kopp [1 ]
Fiala, C. [2 ]
Stephansson, O. [1 ,3 ]
Gemzell-Danielsson, K. [1 ]
机构
[1] Karolinska Univ Hosp, Karolinska Inst, Dept Womens & Childrens Hlth, Div Obstet & Gynaecol, S-17176 Stockholm, Sweden
[2] Gynmed Clin, A-1150 Vienna, Austria
[3] Karolinska Univ Hosp, Karolinska Inst, Dept Med, Clin Epidemiol Unit, S-17176 Stockholm, Sweden
基金
瑞典研究理事会;
关键词
mifepristone; home administration; medical abortion; termination of pregnancy; acceptability; MIFEPRISTONE; ACCEPTABILITY; COMBINATION; PREGNANCY; REGIMEN; TRIAL;
D O I
10.1093/humrep/deq037
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Home use of misoprostol for termination of pregnancy is still controversial in many countries. Acceptability of home use of misoprostol has been investigated in pregnancies below 49 days gestation. In this study, we aimed to assess efficacy, feasibility and acceptability of home use of vaginal misoprostol for medical termination of pregnancy at 50-63 days compared with gestation of below 50 days among women who chose to administer misoprostol at home. In this prospective study, mifepristone 200 mg was given in hospital under nursing supervision in the university hospital outpatient family planning clinic. Women self-administered misoprostol 800 mu g vaginally 36-48 h later at home. Follow-up was 2 weeks later. Women with gestation of 50-63 days on the day of mifepristone administration were compared with women with gestation of below 50 days. Efficacy and feasibility were assessed by review of patient records and questionnaires. Acceptability was assessed using questionnaires where women reported on future choice of abortion method were they to have another abortion. Among the 2992 women who had a medical abortion during the study period, 395 women chose to administer misoprostol at home and were included in the study. A total of 203 women were below 50 days gestation and 192 were between 50 and 63 days gestation. Efficacy was 97.5% and did not differ between the groups. Surgical intervention was needed in 10 patients, of whom four were in the lower gestational band (P = 0.36). No serious adverse events or blood transfusions were reported. Preference for home administration of misoprostol, were they to have another induced abortion in the future, was high, 92.3 and 86.6% respectively, and did not differ between the groups (P = 0.097). Need for extra analgesia significantly influenced women's experiences in both gestational groups. Medical abortion with mifepristone followed by home administration of vaginal misoprostol is safe and highly acceptable also to women with gestational length of 50-63 days as compared with shorter gestations. Efficacy, acceptability and preference for future place of administration of misoprostol, were women to have another abortion, did not differ between women with gestation below 50 days or between 50 and 63 days.
引用
收藏
页码:1153 / 1157
页数:5
相关论文
共 50 条
  • [31] Randomized study of sublingual and oral misoprostol following mitepristone 200 mg for abortion up to 63 days' gestation in moldova
    Raghavan, S.
    Comedant, R.
    Winikoff, B.
    CONTRACEPTION, 2007, 76 (02) : 159 - 160
  • [32] Comparison of vaginal and buccal misoprostol after mifepristone for medication abortion through 70 days of gestation: A retrospective chart review
    Young, Danielle
    Fitzgerald, Kelly
    Laursen, Laura
    Whitaker, Amy K.
    CONTRACEPTION, 2022, 115 : 62 - 66
  • [33] Impact of self-administration of misoprostol for early medical abortion: a prospective observational cohort study
    Finch, Rebecca Elizabeth
    McGeechan, Kevin
    Johnstone, Anne
    Cameron, Sharon
    BMJ SEXUAL & REPRODUCTIVE HEALTH, 2019, 45 (04) : 296 - 301
  • [34] A randomised clinical trial comparing the sublingual and buccal routes of administration of misoprostol after mifepristone for medical termination of pregnancy of up to 63 days of gestation
    Chai, J.
    Wong, C. Y. G.
    Ho, P. C.
    BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2012, 119 : 139 - 139
  • [35] Medical abortion at 57 to 63 days' gestation with a lower dose of mifepristone and gemeprost -: A randomized controlled trial
    Dhall, GI
    Calder, A
    Gomez-Alzugaray, M
    Ho, PC
    Pretnar, AD
    Chen, JK
    Bygdeman, M
    Kovacs, L
    Kavkasidze, G
    Song, LJ
    Van Look, PFA
    von Hertzen, H
    Noonan, E
    Ali, M
    Peregoudov, A
    Laperrière, N
    Grimes, D
    Ali, M
    ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, 2001, 80 (05) : 447 - 451
  • [36] Efficacy and Safety of a Regimen for Medical Abortion up to 63 Days of Gestation: A Retrospective Study in Northern Greece
    Kelesidou, Vera
    Tsakiridis, Ioannis
    Mitta, Kyriaki
    Virgiliou, Andriana
    Michos, Georgios
    Kougioumtsidou, Anna
    Mamopoulos, Apostolos
    Dagklis, Themistoklis
    Kalogiannidis, Ioannis
    JOURNAL OF CLINICAL MEDICINE, 2025, 14 (04)
  • [37] A non-inferiority study of outpatient mifepristone-misoprostol medical abortion at 64-70 days and 71-77 days of gestation
    Dzuba, Ilana G.
    Chong, Erica
    Hannum, Curtiss
    Lichtenberg, E. Steve
    Lugo Hernandez, Elba Margarita
    Nguyen Thi Nhu Ngoc
    Patel, Ashlesha
    Rzayeva, Gulnara
    Sanhueza Smith, Patricio
    Tsertsvadze, George
    Winikoff, Beverly
    CONTRACEPTION, 2020, 101 (05) : 302 - 308
  • [38] Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion - A randomized trial
    Schaff, EA
    Fielding, SL
    Westhoff, C
    Ellertson, C
    Eisinger, SH
    Stadalius, LS
    Fuller, L
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (15): : 1948 - 1953
  • [39] Randomized trial of oral versus vaginal misoprostol 2 days after mifepristone 200 mg for abortion up to 63 days of pregnancy (vol 66, pg 247, 2002)
    Schaff, EA
    Fielding, SL
    Westhoff, C
    CONTRACEPTION, 2002, 66 (06) : 481 - 481
  • [40] Two prophylactic medication approaches in addition to a pain control regimen for early medical abortion < 63 days’ gestation with mifepristone and misoprostol: study protocol for a randomized, controlled trial
    Monica V. Dragoman
    Daniel Grossman
    Nathalie Kapp
    Nguyen My Huong
    Ndema Habib
    Duong Lan Dung
    Anand Tamang
    Reproductive Health, 13